Patents by Inventor Wataru Miyanaga
Wataru Miyanaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10562898Abstract: Provided is a compound having ?4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification.Type: GrantFiled: February 6, 2017Date of Patent: February 18, 2020Assignee: EA PHARMA CO., LTD.Inventors: Munetaka Tokumasu, Masatsugu Noguchi, Mizuki Kawahira, Kana Iwasaki, Nobuhiko Hayakawa, Wataru Miyanaga, Yuki Saitou, Yui Yamaura, Ayatoshi Ando, Atsushi Tsuruta, Misato Noguchi
-
Publication number: 20190040059Abstract: Provided is a compound having ?4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where R1 to R5, e to h, D, and B represent those as described in the specification.Type: ApplicationFiled: February 6, 2017Publication date: February 7, 2019Applicant: EA PHARMA CO., LTD.Inventors: Munetaka TOKUMASU, Masatsugu NOGUCHI, Mizuki KAWAHIRA, Kana IWASAKI, Nobuhiko HAYAKAWA, Wataru MIYANAGA, Yuki SAITOU, Yui YAMAURA, Ayatoshi ANDO, Atsushi TSURUTA, Misto NOGUCHI
-
Patent number: 9440980Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: April 25, 2014Date of Patent: September 13, 2016Assignee: EA PHARMA CO., LTD.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20160046592Abstract: An object is to provide a novel compound which has a glycogen synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe.Type: ApplicationFiled: October 30, 2015Publication date: February 18, 2016Applicant: Ajinomoto Co., Inc.Inventors: Kayo MATSUMOTO, Wataru MIYANAGA, Mizuki DOHI, Tadakiyo NAKAGAWA, Kaori KOBAYASHI, Sen TAKESHITA
-
Publication number: 20140309135Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: April 25, 2014Publication date: October 16, 2014Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki FUKUCHI, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8772281Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: December 10, 2012Date of Patent: July 8, 2014Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8357680Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: GrantFiled: October 7, 2009Date of Patent: January 22, 2013Assignee: Ajinomoto Co., Inc.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Patent number: 8299064Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: GrantFiled: March 4, 2011Date of Patent: October 30, 2012Assignee: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Publication number: 20120088737Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 12, 2012Applicant: AJINOMOTO CO., INCInventors: Wataru MIYANAGA, Yoichiro SHIMA, Misato NOGUCHI, Akiko OONUKI, Yayoi KAWATO, Hiroshi IWATA, Eri HARADA, Ryuta TAKASHITA, Hirokazu UENO, Tadakiyo NAKAGAWA
-
Publication number: 20110160191Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: Ajinomoto Co., Inc.Inventors: Ryusuke HIRAMA, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Patent number: 7951799Abstract: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.Type: GrantFiled: October 29, 2007Date of Patent: May 31, 2011Assignee: Ajinomoto Co., Inc.Inventors: Hideyuki Tanaka, Wataru Miyanaga, Masaru Takayanagi, Ryusuke Hirama, Yoko Kageyama, Tatsuya Ishikawa, Itsuya Tanabe, Yoriko Okamatsu
-
Patent number: 7928101Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: GrantFiled: May 1, 2006Date of Patent: April 19, 2011Assignee: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi
-
Publication number: 20110082109Abstract: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AJINOMOTO CO., INC.Inventors: Wataru MIYANAGA, Yoichiro Shima, Misato Noguchi, Akiko Oonuki, Yayoi Kawato, Hiroshi Iwata, Eri Harada, Ryuta Takashita, Hirokazu Ueno, Tadakiyo Nakagawa
-
Publication number: 20100093973Abstract: Herein disclosed is a water-soluble compound represented by the following general formula (I) or a salt thereof. The compound is a novel water-soluble compound having an inhibitory effect on the absorption of phosphorus in vivo. where the structural variables are defined herein.Type: ApplicationFiled: August 27, 2009Publication date: April 15, 2010Applicant: AJINOMOTO CO., INC.Inventors: Tadakiyo Nakagawa, Hironobu Tsugeno, Naomi Matsutani, Masayuki Sugiki, Haruko Hirashima, Tatsuya Okuzumi, Tatsuya Kasahara, Wataru Miyanaga, Takashi Yamamoto, Masatsugu Noguchi, Kayo Matsumoto, Hideyuki Tanaka, Tomoyuki Konda
-
Publication number: 20100093055Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: October 7, 2009Publication date: April 15, 2010Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki Fukuchi, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20080108604Abstract: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.Type: ApplicationFiled: October 29, 2007Publication date: May 8, 2008Applicant: Ajinomoto Co., Inc.Inventors: Hideyuki Tanaka, Wataru Miyanaga, Masaru Takayanagi, Ryusuke Hirama, Yoko Kageyama, Tatsuya Ishikawa, Itsuya Tanabe, Yoriko Okamatsu
-
Publication number: 20060194789Abstract: The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R? represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R? represent a hydrogen atom.Type: ApplicationFiled: May 1, 2006Publication date: August 31, 2006Applicant: Ajinomoto Co., Inc.Inventors: Ryusuke Hirama, Seiji Niwa, Hideyuki Tanaka, Toshihiro Hatanaka, Yoko Masuzawa, Akiyo Yamazaki, Takao Ikenoue, Nobuo Kondo, Wataru Miyanaga, Masaru Takayanagi